A phase Ib study evaluating safety, pharmacokinetic and pharmacodynamic profiles of a single course of TL011 infusions in subjects with severe, active rheumatoid arthritis .
Phase of Trial: Phase I
Latest Information Update: 10 Jun 2016
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Teva Pharmaceutical Industries
- 14 May 2012 Actual end date May 2012 added as reported by ClinicalTrials.gov.
- 14 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Jan 2012 Actual patient number (48) added as reported by ClinicalTrials.gov.